Organon Inks Licensing Pact For Daré Bioscience’s Bacterial Vaginosis Treatment
Organon & Co (NYSE: OGN)
Recap: Dare Bioscience Q4 Earnings
Dare Bioscience (NASDAQ:DARE) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Earnings Preview: Dare Bioscience
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement.
Analysts estimate that Dare Bioscience will report an earnings per share (EPS) of $-0.15.
35 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options to maximize shareholder value, including potential merger or acquisition.
BZ Chart Of The Day: Dare Bioscience
If markets have memories, shares of Daré Bioscience, Inc. (NASDAQ: DARE) may be in trouble. The stock has run into a resistance level.
Resistance is a large group of sellers offering their shares at or close to the same price. In this case, it’s $2.40.
22 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Daré Bioscience, Inc. (NASDAQ: DARE) rose 45.2% to $3.08 in pre-market trading after the company reported the FDA approval of XACIATO Vaginal Gel as a treatment for bacterial vaginosis.